Autres langues Gland Pharma Limited Bombay S.E.

Actions

GLAND

INE068V01023

Marché Fermé - Bombay S.E. Autres places de cotation 12:00:47 30/04/2024			Varia. 5j.	Varia. 1 janv.
1 711 ^INR	-0,95 %		-3,70 %	-11,03 %

29/04	Gland Pharma nomme son directeur des opérations	MT
29/04	Gland Pharma Limited approuve la nomination de M. Satnam Singh Loomba au poste de Chief Operating Officer, à compter du 1er mai 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Gland Pharma Names COO	29/04
Gland Pharma Limited Approves Appointment of Mr. Satnam Singh Loomba as Chief Operating Officer, Effective May 1 ,2024	29/04
Gland Pharma Gets US FDA's Final Approval for Generic Drug for Luteinizing Hormone Surges	29/04
Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals	08/04
Gland Pharma Gets US FDA Approval for Eribulin Mesylate Injection	08/04
Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Eribulin Mesylate Injection 0.5 Mg/ML Single Dose Vial	06/04
Gland Pharma COO, Chief Technical Officer Step Down	25/03
Gland Pharma Limited Announces Change in Management	25/03
Gland Pharma Names New President of Phixen Subsidiary	27/02
Gland Pharma's Consolidated Profit Drops in Fiscal Q3	15/02
Gland Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02
Indian shares set to open lower as hot US inflation spurs rate worries	14/02
Gland Pharma Gets Establishment Inspection Report from US FDA for Pashamylaram Unit	24/11
32,656,565 Equity Shares of Gland Pharma Limited are subject to a Lock-Up Agreement Ending on 18-NOV-2023.	18/11
Gland Pharma Gets US FDA's Tentative Approval for Generic Hypotension Drug	15/11
Gland Pharma Limited Receives Tentative Approval for Angiotensin II Injection	15/11
Abbott India's Q2 profit climbs on strong sales	09/11
Gland Pharma Gets US FDA's EIR Report Closing Inspection of Visakhapatnam, India Unit	08/11
Indian shares set to open marginally higher	07/11
India's Gland Pharma misses Q2 profit view on higher expenses	06/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Gland Pharma Limited Bombay S.E.

Actions

GLAND

INE068V01023

Autres langues

Filtres